GL1X · GenesisL1 explorer

MolNFT v1 · #104880 · protein

Crystal structure of rhomboid intramembrane protease glpg in complex with peptide derived inhibitor ac-iata-cmk

4QO2 · Rhomboid protease glpg: “Crystal structure of rhomboid intramembrane protease glpg in complex with peptide derived inhibitor…”. X-ray diffraction, 4 ligands (BNG, ACE, 0QE), 1 pocket (best druggability 0.37). MolNFT v1 #104880 on…

PDB
4QO2
Type
protein
Length
186 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Rhomboid protease glpg; 6-amino-2-methyl-1,7-dihydro-8H-IMIDAZO[4,5-G]QUINAZOLIN-8- one
EC
3.4.21.105
UniProt
U6NA71
Ligands
BNG, ACE, 0QE, CL
Pockets
1 · best druggability 0.37

Structure

x-ray diffraction · 2 distinct chains · 73% helix, 3% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARhomboid protease glpg (EC 3.4.21.105)protein18275% helix, 2% strandU6NA71
B6-amino-2-methyl-1,7-dihydro-8H-IMIDAZO[4,5-G]QUINAZOLIN-8- oneprotein40% helix, 50% strand—

Ligands and binding sites

  • BNG · nonyl beta-D-glucopyranoside · ligand · 14 copies · chains A
  • ACE · Acetyl group · ligand · chains A, B
  • 0QE · Chloromethane · ion · chains A, B
  • CL · Chloride ion · ion · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1760.370.7616BNG

Interfaces

1 interface between chains.

  • A–B · 395 Ų buried · 7 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 4QO2 · Crystal structure of rhomboid intramembrane protease GlpG in complex with peptide derived… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.